Sarepta Therapeutics, Inc. (SRPT)

Market Cap	6.97B
Revenue (ttm)	1.90B
Net Income (ttm)	235.24M
Shares Out	97.03M
EPS (ttm)	2.34
PE Ratio	30.71
Forward PE	8.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,364,422
Open	72.98
Previous Close	72.88
Day's Range	71.25 - 73.95
52-Week Range	70.91 - 173.25
Beta	0.79
Analysts	Buy
Price Target	164.05 (+128.45%)
Earnings Date	Apr 30, 2025

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 1997
• Employees: 1,372
• Stock Exchange: NASDAQ
• Ticker Symbol: SRPT
• Website: https://www.sarepta.com

Analyst Forecast

According to 21 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $164.05, which is an increase of 128.45% from the latest price.

Price Target

$164.05

(128.45% upside)

Analyst Consensus: Buy